225Ac imaging of NK1-targeted α-particle for glioblastoma radiotherapy
Treatments for glioblastoma (GB) are critically insufficient. We aim to develop an efficient therapy based on a molecularly-specific-delivery of the extremely potent long-lived α particle 225Ac. Substance P (SP) binds neurokinin receptors NK1, overexpressed in GB. Recently, targeted therapies using 90Y- or 213Bi-labeled SPs have emerged as potent options but are either toxic or insufficient. Via 225Ac-SP intracranial delivery, we intend to longitudinally treat GB and eradicate disseminated brain tumors.
ABOU Diane;
GUERRERO-CAZARES H;
MINN Il;
POMPER Martin;
QUINONES-HINOJOSA Alfredo;
MORGENSTERN Alfred;
BACK Tom;
HOBBS Robert F.;
WAHL Richard;
SGOUROS George;
2014-08-27
SOC NUCLEAR MEDICINE INC
JRC88667
0161-5505,
http://jnumedmtg.snmjournals.org/cgi/content/meeting_abstract/55/1_MeetingAbstracts/393,
https://publications.jrc.ec.europa.eu/repository/handle/JRC88667,
Additional supporting files
| File name | Description | File type | |
|---|
